438 related articles for article (PubMed ID: 12365868)
1. Polycythemia vera--a case report and discussion on pathogenic mechanisms of increased thrombosis.
Gumina RJ; Foley DA; Tefferi A; Rooke TW; Shields RC
Angiology; 2002; 53(5):587-91. PubMed ID: 12365868
[TBL] [Abstract][Full Text] [Related]
2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
3. Daily aspirin--only half the answer.
Spivak J
N Engl J Med; 2004 Jan; 350(2):99-101. PubMed ID: 14711906
[No Abstract] [Full Text] [Related]
4. Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
Das S; Karachiwala H; Cherian SV; Garcha AS; Jasti S; Gajra A
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):746-8. PubMed ID: 21885951
[TBL] [Abstract][Full Text] [Related]
5. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T;
N Engl J Med; 2004 Jan; 350(2):114-24. PubMed ID: 14711910
[TBL] [Abstract][Full Text] [Related]
7. Polycythaemia Vera Presenting As A Porta Hepatis Mass.
Ahmed S; Irfan O; Siddique S; Abid S
J Ayub Med Coll Abbottabad; 2019; 31(4):627-628. PubMed ID: 31933324
[TBL] [Abstract][Full Text] [Related]
8. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi R; Di Gennaro L
Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
[No Abstract] [Full Text] [Related]
9. Erythromelalgia and vascular complications in polycythemia vera.
Michiels JJ
Semin Thromb Hemost; 1997; 23(5):441-54. PubMed ID: 9387203
[TBL] [Abstract][Full Text] [Related]
10. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.
Barbui T; Carobbio A; Ghirardi A; Masciulli A; Rambaldi A; Vannucchi AM
Haematologica; 2017 Jun; 102(6):e219-e221. PubMed ID: 28255021
[No Abstract] [Full Text] [Related]
11. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
12. Bumpy road to the diagnosis of polycythaemia vera.
Gameiro RS; Rodrigues A; Gonçalves FM; Graça JP
BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28280082
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and therapy of polycythemia vera.
Lengfelder E; Merx K; Hehlmann R
Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
[TBL] [Abstract][Full Text] [Related]
14. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
[TBL] [Abstract][Full Text] [Related]
16. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
17. Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
Friess D; Lämmle B; Alberio L
Hamostaseologie; 2003 Aug; 23(3):138-43. PubMed ID: 12923585
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic complications of polycythemia. The venous and arterial risk factors.
Fiessinger JN
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):179-81. PubMed ID: 8036138
[TBL] [Abstract][Full Text] [Related]
19. Thromboembolic events in polycythemia vera.
Griesshammer M; Kiladjian JJ; Besses C
Ann Hematol; 2019 May; 98(5):1071-1082. PubMed ID: 30848334
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.
Ann Intern Med; 1995 Nov; 123(9):656-64. PubMed ID: 7574220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
